HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by SCHLAFF, W. D. Articles by ROCK, J. A. Search for Related Content PubMed PubMed Citation Articles by SCHLAFF, W. D. Articles by ROCK, J. A.

A Placebo-Controlled Trial of a Depot Gonadotropin-Releasing Hormone Analogue (Leuprolide) in the Treatment of Uterine Leiomyomata

From the Division of Reproductive Endocrinology, Department of Gynecology and Obstetrics, and the Departments of Radiology and Nuclear Medicine, Johns Hopkins Medical Institutions, Baltimore, Maryland

Abstract

Several studies have shown that treatment with a gonadotropin- releasing hormone (GnRH) analogue can reduce uterine volume in women with leiomyomata. However, no study to date has used a controlled population for comparison, nor has any study delineated the physiologic mechanism of volume reduction. We performed a double-blind, placebo-controlled study of a depot form of a GnRH analogue (leuprolide) given monthly for 24 weeks in 11 patients with symptomatic uterine leiomyomata. Patients initially treated with placebo were subsequently treated with active drug for 24 weeks. Magnetic resonance imaging was used to identify specifically the total uterine volume, total myoma volume, and total non-myoma volume. Treated patients had a significant reduction in total uterine and non-myoma volumes as compared with placebo patients (P < .02). Total myoma volume was also reduced, but only to a P=.06 level. Pre- versus post-therapy values for all 11 patients showed significant reduction in all three volumes (P < .02). Most symptoms were markedly improved. By 24 weeks post-therapy, all volumes had returned to baseline levels, although symptomatic improvement commonly persisted. The non-myoma volume was proportionally reduced to a greater extent than the myoma volume (42.7 versus 30.4%), and we therefore could explain the reenlargement seen when treatment was discontinued. Side effects were well tolerated and there were no study dropouts. We conclude that temporary hypoestrogenism induced by GnRH analogues can produce significant though temporary reduction in uterine volumes, and that the non-myoma volume is responsible for much of the reduction and reenlargement. The treatment is well tolerated, and symptomatic benefits may well persist even with return of uterine volumes to pre-treatment size.

This article has been cited by other articles:

				F. K. Varelas, A. N. Papanicolaou, N. Vavatsi-Christaki, G. A. Makedos, and G. D. Vlassis The Effect of Anastrazole on Symptomatic Uterine Leiomyomata Obstet. Gynecol., September 1, 2007; 110(3): 643 - 649. [Abstract] [Full Text] [PDF]

				E. E. Wallach and N. F. Vlahos Uterine Myomas: An Overview of Development, Clinical Features, and Management Obstet. Gynecol., August 1, 2004; 104(2): 393 - 406. [Abstract] [Full Text] [PDF]

				E. R. Myers, M. D. Barber, T. Gustilo-Ashby, G. Couchman, D. B. Matchar, and D. C. McCrory Management of Uterine Leiomyomata: What Do We Really Know? Obstet. Gynecol., July 1, 2002; 100(1): 8 - 17. [Abstract] [Full Text] [PDF]

				K. Englund, A. Blanck, I. Gustavsson, U. Lundkvist, P. Sjöblom, A. Norgren, and B. Lindblom Sex Steroid Receptors in Human Myometrium and Fibroids: Changes during the Menstrual Cycle and Gonadotropin-Releasing Hormone Treatment J. Clin. Endocrinol. Metab., November 1, 1998; 83(11): 4092 - 4096. [Abstract] [Full Text]